Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $26.6 million.

  • Ani Pharmaceuticals' Profit After Tax rose 21014.23% to $26.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.6 million, marking a year-over-year increase of 67214.78%. This contributed to the annual value of -$18.5 million for FY2024, which is 19863.15% down from last year.
  • Ani Pharmaceuticals' Profit After Tax amounted to $26.6 million in Q3 2025, which was up 21014.23% from $8.5 million recorded in Q2 2025.
  • Ani Pharmaceuticals' Profit After Tax's 5-year high stood at $26.6 million during Q3 2025, with a 5-year trough of -$24.2 million in Q3 2024.
  • Its 5-year average for Profit After Tax is -$2.1 million, with a median of -$2.3 million in 2024.
  • As far as peak fluctuations go, Ani Pharmaceuticals' Profit After Tax tumbled by 2350697.67% in 2022, and later soared by 116525.36% in 2024.
  • Ani Pharmaceuticals' Profit After Tax (Quarter) stood at -$24.1 million in 2021, then skyrocketed by 82.42% to -$4.2 million in 2022, then surged by 127.22% to $1.2 million in 2023, then plummeted by 989.7% to -$10.3 million in 2024, then soared by 359.02% to $26.6 million in 2025.
  • Its last three reported values are $26.6 million in Q3 2025, $8.5 million for Q2 2025, and $15.7 million during Q1 2025.